Human Pentraxin 3 (PTX3) as a Novel Biomarker for the Diagnosis of Pulmonary Arterial Hypertension

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Tamura, Yuichi ^a   Ono, Tomohiko ^a   Kuwana, Masataka ^a   Inoue, Kenji ^b   Takei, Makoto ^a   Yamamoto, Tsunehisa ^a   Kawakami, Takashi ^a   Fujita, Jun ^a   Kataoka, Masaharu ^c   Kimura, Kensuke ^a   Sano, Motoaki ^a   Daida, Hiroyuki ^d   Satoh, Toru ^c   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ENDOTHELIN RECEPTOR ANTAGONIST; PENTRAXIN 3; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; FALSE NEGATIVE RESULT; FEMALE; HUMAN; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

AREA UNDER CURVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; ROC CURVE; SERUM AMYLOID P-COMPONENT;

EID: 84866721758     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045834     Document Type: Article

References (30)

1. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, et al. (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54: S55-66.
2. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society, endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: 2493-2537.
3. Launay D, Mouthon L, Hachulla E, Pagnoux C, de Groote P, et al. (2007) Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 34: 1005-1011.
4. Mukerjee D, St George D, Knight C, Davar J, Wells AU, et al. (2004) Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 43: 461-466.
5. Hinchcliff M, Fischer A, Schiopu E, Steen VD, (2011) Pulmonary hypertension assessment and recognition of outcomes in scleroderma (pharos): Baseline characteristics and description of study population. J Rheumatol 38: 2172-2179.
6. Schreiber BE, Valerio CJ, Keir GJ, Handler C, Wells AU, et al. (2011) Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum 63: 3531-3539.
7. Cavagna L, Caporali R, Klersy C, Ghio S, Albertini R, et al. (2010) Comparison of brain natriuretic peptide (bnp) and nt-probnp in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 37: 2064-2070.
8. Williams MH, Handler CE, Akram R, Smith CJ, Das C, et al. (2006) Role of n-terminal brain natriuretic peptide (n-tprobnp) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 27: 1485-1494.
9. Garlanda C, Bottazzi B, Bastone A, Mantovani A, (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23: 337-366.
10. Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, et al. (2003) Production of the soluble pattern recognition receptor ptx3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 33: 2886-2893.
11. Mantovani A, Garlanda C, Doni A, Bottazzi B, (2008) Pentraxins in innate immunity: From c-reactive protein to the long pentraxin ptx3. J Clin Immunol 28: 1-13.
12. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, et al. (2000) PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 102: 636-641.
13. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, et al. (2007) Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 27: 161-167.
14. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, et al. (2006) The long pentraxin ptx3 in vascular pathology. Vascul Pharmacol 45: 326-330.
15. Ishihara T, Haraguchi G, Kamiishi T, Tezuka D, Inagaki H, et al. (2011) Sensitive assessment of activity of takayasu's arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol 57: 1712-1713.
16. Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, et al. (2011) Pentraxin-3 as a marker of disease activity in takayasu arteritis. Ann Intern Med 155: 425-433.
17. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, et al. (2009) Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 47: 471-7.
18. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, et al. (2008) Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 155: 75-81.
19. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, et al. (2011) Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 57: 861-869.
20. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF, (2005) Autoimmunity and pulmonary hypertension: A perspective. Eur Respir J 26: 1110-1118.
21. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, et al. (2006) Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 54: 3043-3050.
22. Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, et al. (2004) Selective recognition of fibroblast growth factor-2 by the long pentraxin ptx3 inhibits angiogenesis. Blood 104: 92-99.
23. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, et al. (2008) Expression of pentraxin 3 (ptx3) in human atherosclerotic lesions. J Pathol 215: 48-55.
24. Norata GD, Garlanda C, Catapano AL, (2010) The long pentraxin ptx3: A modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 20: 35-40.
25. Presta M, Camozzi M, Salvatori G, Rusnati M, (2007) Role of the soluble pattern recognition receptor ptx3 in vascular biology. J Cell Mol Med 11: 723-738.
26. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, et al. (2002) Long pentraxin ptx3 upregulates tissue factor expression in human endothelial cells: A novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol 22: 782-787.
27. Vergadi E, Chang MS, Lee C, Liang OD, Liu X, et al. (2011) Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation 123: 1986-1995.
28. Christmann RB, Hayes E, Pendergrass S, Padilla C, Farina G, et al. (2011) Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum 63: 1718-1728.
29. Grigoryev DN, Mathai SC, Fisher MR, Girgis RE, Zaiman AL, et al. (2008) Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res 151: 197-207.
30. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, et al. (2010) Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 5: e12106.